

June 8, 2016



Actinium to Present at BIO International Convention to Provide Updates on Actimab-A and Iomab-B Programs

Recent Actimab-A Phase 1 Data and Key Discovery From Its HuM195-Alpha Program Will Be Featured Along With Highlights of Actinium's Lead Program Iomab-B

NEW YORK, NY -- (Marketwired) -- 06/08/16 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Sandesh Seth, Executive Chairman, will be presenting at the 2016 BIO International Convention. Actinium's presentation will highlight developments from the Company's Actimab-A program, which recently completed the Phase 1 portion of its Phase 1/2 trial in patients newly diagnosed with Acute Myeloid Leukemia (AML) over the age of 60 and will be progressing to the Phase 2 portion of the trial. The Company will also highlight its key discovery that peripheral blast (PB) burden plays a significant role in patient responses to Actimab-A, with low PB burden patients achieving higher response rates. Actinium reported a 50% response rate at the highest dose level in the Phase 1 trial in patients with low PB burden and that PB burden can be reduced using hydroxyurea, which will be mandated in the Phase 2 trial. Finally, Actinium will highlight Iomab-B, which is intended to be an induction and conditioning agent prior to a bone marrow transplant (BMT) and will soon begin a pivotal Phase 3 trial in patients with relapsed or refractory AML over the age of 55.

Presentation information

Date: June 8, 2016 Time: 4:30 PM PDT Location: Theater #1, 2nd Floor, West Exhibit Hall, Moscone Center, San Francisco, California

Sandesh Seth, Actinium's Executive Chairman, said, "BIO International has proven to be an excellent experience for Actinium and one that has afforded us the opportunity to meet with representatives from organizations from across the globe. We look forward to presenting Actinium's progress, particularly our recent Actimab-A Phase 1 data and our key discovery related to peripheral blast burden to the global audience at BIO International."

Members of Actinium's management team will be available for one-on-one meetings with conference attendees. To arrange a meeting with management, please contact Steve O'Loughlin, Actinium's Vice President, Finance and Corporate Development, at soloughlin@actiniumpharma.com or make a request through the BIO One-on-One Partnering™ system <http://convention.bio.org/partner/>.

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy program, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. Actimab-A is being developed as a first line therapy and has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. Both the alpha particle technology and Lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.

About Iomab-B

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for a hematopoietic stem cell transplantation, referred to as a bone marrow transplant, in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ

materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin

Vice President, Finance and Corporate Development

Actinium Pharmaceuticals, Inc.

soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals